. Author manuscript; available in PMC: 2011 Jan 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 Feb 16;16(7):1005–1017. doi: 10.1016/j.bbmt.2010.02.009

Table 6. Summary of Central Pathology Review Findings.

Pathology Finding	All Patients with Pathology Assessment (Evaluable for Day +100 Post-HSCT Survival) (n = 52)^*	Patients with Pathology Assessment Who Were Evaluable for Response (n = 47)^*
VOD, n (%)	33 (63)	31 (66)
VOD plus another histologic diagnosis, n (%)	5 (10)	5 (11)
Findings consistent with, but not diagnostic of, VOD, n (%)	3 (6)	3 (6)
Alternative diagnosis, n (%)^†	10 (19)	8 (17)
GVHD, n (%)	4 (8)	4 (9)
Insignificant for diagnosis, n (%)	1 (2)	0 (0)

HSCT indicates hematopoietic stem cell transplantation; VOD, veno-occlusive disease; GVHD, graft-versus-host disease.

One patient had no VOD on liver biopsy and was excluded before initiation of defibrotide. One patient had no VOD on liver biopsy performed after initiation of defibrotide; this patient was removed from the trial.

^†

In addition to the 4 patients with possible, probable, or definite GVHD, alternative diagnoses were cirrhosis in 2 patients and viral hepatitis, shock, abscesses, and GVHD or cholangitis lenta each in 1 patient.